Targeting the MasR with Ang-(1–7) is showing promising results in experimental stroke models however, Ang-(1–7) has a 20 s half life in the bloodstream and is unlikely to cross the BBB therefore necessitating specific receptor agonists to be developed with improved pharmacokinetic profiles [79]. This evidence concerns the gene MAS1L and Stroke.